SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS; A HIGH NUMBER OF PATIENTS ACHIEVE DOPPLER REMISSION AFTER 24 WEEKS

被引：0
|
作者：
Hammer, H. B. [1 ]
Hansen, I. M. J. [2 ]
Jarvinen, P. [3 ]
Leirisalo-Repo, M. [4 ,5 ]
Ziegelasch, M. [6 ]
Agular, B. [7 ]
Terslev, L. [8 ]
机构：
[1] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway
[2] Svendborg Hosp, Dept Rheumatol, Svendborg, Denmark
[3] Kiljavan Laaketutkimus, Dept Rheumatol, Kiljavan, Finland
[4] Helsinki Univ Hosp, Dept Rheumatol, Helsinki, Finland
[5] Univ Helsinki, Helsinki, Finland
[6] Univ Hosp, Dept Rheumatol, Linkoping, Sweden
[7] Roche, Dept Med, Copenhagen, Denmark
[8] Copenhagen Univ Hosp Glostrup, Ctr Rheumatol & Spinal Dis, Copenhagen, Denmark
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.3533
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0200
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [31] PREDICTING JOINT AND SKIN REMISSION AT 24 WEEKS IN PATIENTS WITH PSORIATIC ARTHRITIS
    Dougados, Maxime
    Keystone, Edward
    Heckaman, Michele
    Mease, Philip
    RHEUMATOLOGY, 2012, 51 : 87 - 88
  • [32] Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
    Jean Darloy
    Nicolas Segaud
    Jean-Hugues Salmon
    Jean-Paul Eschard
    Vincent Goëb
    Xavier Deprez
    Marie-Hélène Guyot
    Eric Houvenagel
    Nicolas Lecuyer
    Laurent Marguerie
    Samuel Gally
    David Pau
    Isabelle Idier
    Guy Baudens
    René-Marc Flipo
    Rheumatology and Therapy, 2019, 6 : 61 - 75
  • [33] Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
    Darloy, Jean
    Segaud, Nicolas
    Salmon, Jean-Hugues
    Eschard, Jean-Paul
    Goeb, Vincent
    Deprez, Xavier
    Guyot, Marie-Helene
    Houvenagel, Eric
    Lecuyer, Nicolas
    Marguerie, Laurent
    Gally, Samuel
    Pau, David
    Idier, Isabelle
    Baudens, Guy
    Flipo, Rene-Marc
    RHEUMATOLOGY AND THERAPY, 2019, 6 (01) : 61 - 75
  • [34] Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series
    Talotta R.
    Atzeni F.
    Batticciotto A.
    Ditto M.C.
    Gerardi M.C.
    Sarzi-Puttini P.
    Journal of Medical Case Reports, 12 (1)
  • [35] Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis
    Iwamoto, Naoki
    Fukui, Shoichi
    Umeda, Masataka
    Nishino, Ayako
    Nakashima, Yoshikazu
    Suzuki, Takahisa
    Horai, Yoshiro
    Nonaka, Fumiaki
    Okada, Akitomo
    Koga, Tomohiro
    Kawashiri, Shin-ya
    Fujikawa, Keita
    Aramaki, Toshiyuki
    Ichinose, Kunihiro
    Hirai, Yasuko
    Tamai, Mami
    Nakamura, Hideki
    Terada, Kaoru
    Nakashima, Munetoshi
    Mizokami, Akinari
    Origuchi, Tomoki
    Eguchi, Katsumi
    Ueki, Yukitaka
    Kawakami, Atsushi
    MODERN RHEUMATOLOGY, 2016, 26 (05) : 662 - 666
  • [36] EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS OVERLAP SYNDROME
    Wakabayashi, H.
    Kino, S.
    Hasegawa, M.
    Sudo, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1518 - 1519
  • [37] Immunogenicity of tocilizumab in patients with rheumatoid arthritis
    Sigaux, Johanna
    Hamze, Moustafa
    Daien, Claire
    Morel, Jacques
    Krzysiek, Roman
    Pallardy, Marc
    Maillere, Bernard
    Mariette, Xavier
    Miceli-Richard, Corinne
    JOINT BONE SPINE, 2017, 84 (01) : 39 - 45
  • [38] In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline
    Kawashiri, Shin-ya
    Kawakami, Atsushi
    Iwamoto, Naoki
    Fujikawa, Keita
    Aramaki, Toshiyuki
    Tamai, Mami
    Yamasaki, Satoshi
    Nakamura, Hideki
    Origuchi, Tomoki
    Ueki, Yukitaka
    Migita, Kiyoshi
    Mizokami, Akinari
    Aoyagi, Kiyoshi
    Eguchi, Katsumi
    MODERN RHEUMATOLOGY, 2011, 21 (04) : 370 - 374
  • [39] The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA).
    Kivitz, Alan
    Olech, Ewa
    Borofsky, Michael A.
    Zazueta, Beatriz M.
    Navarro-Sarabia, Federico
    Radominski, Sebastiao C.
    Merrill, Joan T.
    Wells, Chris
    Wimalasundera, Sunethra
    Douglass, Wendy
    Pope, Janet E.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S604 - S605
  • [40] ASSESSMENT OF POWER DOPPLER SYNOVITIS IN RHEUMATOID ARTHRITIS PATIENTS WITH CLINICAL REMISSION
    Fakhfakh, R.
    El Amri, N.
    Baccouche, K.
    Zeglaoui, H.
    Bouajina, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1390 - 1390
12345